Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase 3 Completed
1,449 enrolled 17 charts
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Phase 1 Completed
16 enrolled
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Phase 1 Completed
12 enrolled 12 charts
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
21 enrolled 11 charts
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Phase 1 Completed
15 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase 1/2 Completed
140 enrolled 23 charts
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 1/2 Completed
76 enrolled 25 charts
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Phase 2 Completed
73 enrolled 12 charts
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed
1,720 enrolled
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
Phase 1 Completed
33 enrolled
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
Phase 1 Completed
34 enrolled 19 charts
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Phase 1/2 Completed
44 enrolled 13 charts
Informed Consent in Pediatric Cancer Trials
Completed
1 enrolled
Tabectedin to Treat Children and Adolescents With Cancer
Phase 1 Completed
12 enrolled
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase 1 Completed
29 enrolled
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
Phase NA Completed
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Phase 3 Completed
500 enrolled
Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma
Phase 2 Completed
44 enrolled
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
Phase 1 Completed
85 enrolled
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma
Phase 3 Completed
100 enrolled
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
Phase 2 Completed
70 enrolled
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
Phase 1 Completed
21 enrolled
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
Phase 2 Completed
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma
Phase 2 Completed
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma
Phase 2 Completed
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
Phase 2 Completed
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma
Phase 3 Completed
Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
Phase 1 Completed
3 enrolled
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
10 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Caspofungin Acetate in Treating Children With Fever and Neutropenia
Phase NA Completed
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Phase 1 Completed
21 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Phase 1 Completed
18 enrolled
Fenretinide in Treating Children With Solid Tumors
Phase 1 Completed
18 enrolled